drugset
drugset / Trial / NCT03346668

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668 ↗

Phase 0 Completed 5 enrolled University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

This study will serve as a pilot study to determine the efficacy and safety of topical gabapentin in the treatment of symptomatic scarring alopecia.

Timeline

Start
2016-01-28
Primary completion
2021-10-11
Completion
2021-10-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 6 % Topical

Indications

central centrifugal cicatricial alopecia frontal fibrosing alopecia lichen planopilaris